SCHEMBL420309

SCHEMBL420309

Cc1nn(-c2ccc(C(N)=O)c(NC3CCC(O)CC3)c2)c2cccc(-c3cnc4ccccc4c3)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13190306 1.00 HSP90AA1 (1.00) HSP90AA1
SCHEMBL420310 1.00 HSP90AA1 (1.00) HSP90AA1
SCHEMBL422561 0.92 HSP90AA1 (0.85) HSP90AA1
SCHEMBL2693240 0.91 HSP90AA1 (1.00) HSP90AA1
SCHEMBL2693241 0.91 HSP90AA1 (1.00) HSP90AA1
SCHEMBL10215201 0.91 HSP90AA1 (0.83) HSP90AA1
SCHEMBL1394578 0.91 HSP90AA1 (0.83) HSP90AA1
SCHEMBL1394579 0.91 HSP90AA1 (0.83) HSP90AA1
SCHEMBL458829 0.89 HSP90AA1 (0.84) HSP90AA1
SCHEMBL13190077 0.89 HSP90AA1 (0.84) HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408762-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI (FR) 2012-01-25 EP claimed
WO-2010106290-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI-AVENTIS (FR) 2010-09-23 WO claimed
EP-2662367-B1 NOVEL INDOLE OR INDAZOLE DERIVATIVE OR SALT THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2016-08-17 EP disclosed
US-9120780-B2 Indole or indazole derivative or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-09-01 US disclosed
US-9120780-B2 Indole or indazole derivative or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-09-01 US disclosed
EP-2662367-A1 NOVEL INDOLE OR INDAZOLE DERIVATIVE OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2013-11-13 EP disclosed
US-20130289072-A1 NOVEL INDOLE OR INDAZOLE DERIVATIVE OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2013-10-31 US disclosed
US-20130289072-A1 NOVEL INDOLE OR INDAZOLE DERIVATIVE OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2013-10-31 US disclosed
EP-2408762-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI (FR) 2012-01-25 EP disclosed
US-20120010241-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI (FR) 2012-01-12 US disclosed
WO-2010106290-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI-AVENTIS (FR) 2010-09-23 WO disclosed
WO-2010106290-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI-AVENTIS (FR) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010241-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF HSP90AB2P, HSP90AB1, HSP90AA1 HSP90AA1 3/4885
US-20130289072-A1 NOVEL INDOLE OR INDAZOLE DERIVATIVE OR SALT THEREOF HSP90AB1, HSP90AA1, HSP90AB2P HSP90AA1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.